Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

T2 Biosystems CS (TTOO)

T2 Biosystems CS (TTOO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1102 -0.0098 (-8.17%) 03/28/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.1102 unch (unch) 15:39 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1040
Day High
0.1300
Open 0.1200
Previous Close 0.1200 0.1200
Volume 75,600 75,600
Avg Vol 124,100 124,100
Stochastic %K 37.05% 37.05%
Weighted Alpha -96.42 -96.42
5-Day Change -0.0068 (-5.81%) -0.0068 (-5.81%)
52-Week Range 0.0560 - 6.8000 0.0560 - 6.8000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 2,319
  • Shares Outstanding, K 21,043
  • Annual Sales, $ 7,190 K
  • Annual Income, $ -50,080 K
  • EBIT $ -42 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.34
  • Price/Sales 0.18
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.89
  • Most Recent Earnings $-0.57 on 11/14/24
  • Next Earnings Date 04/07/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1035 +6.47%
on 03/19/25
Period Open: 0.1250
0.1450 -24.00%
on 03/07/25
-0.0148 (-11.84%)
since 02/28/25
3-Month
0.0560 +96.79%
on 02/14/25
Period Open: 0.4250
0.4590 -75.99%
on 12/30/24
-0.3148 (-74.07%)
since 12/27/24
52-Week
0.0560 +96.79%
on 02/14/25
Period Open: 3.0000
6.8000 -98.38%
on 06/24/24
-2.8898 (-96.33%)
since 03/28/24

Most Recent Stories

More News
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOO : 0.1102 (-8.17%)
T2 Biosystems Expands International Market Presence with Sale of Four T2Dx® Instruments to European Distributor

T2 Biosystems sold four T2Dx® Instruments to expand its international presence in sepsis-testing technology.Quiver AI SummaryT2 Biosystems, Inc. announced the sale of four T2Dx® Instruments to its European...

TTOO : 0.1102 (-8.17%)
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOO : 0.1102 (-8.17%)
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOO : 0.1102 (-8.17%)
T2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection Products

T2 Biosystems extends its agreement with Vizient, enhancing hospital access to rapid sepsis diagnostics through 2026.Quiver AI SummaryT2 Biosystems, Inc. has announced the extension of its supplier agreement...

TTOO : 0.1102 (-8.17%)
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOO : 0.1102 (-8.17%)
T2 Biosystems Announces Licensing Plans to Enhance Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

T2 Biosystems announced plans to license its technology for direct-from-whole-blood detection of sepsis-causing pathogens, aiming to expand market access.Quiver AI SummaryT2 Biosystems, Inc. has announced...

TTOO : 0.1102 (-8.17%)
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

TTOO : 0.1102 (-8.17%)
T2 Biosystems: Q3 Earnings Snapshot

T2 Biosystems: Q3 Earnings Snapshot

TTOO : 0.1102 (-8.17%)
T2 Biosystems Announces Third Quarter 2024 Financial Results

TTOO : 0.1102 (-8.17%)

Business Summary

T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens,...

See More

Key Turning Points

3rd Resistance Point 0.1515
2nd Resistance Point 0.1407
1st Resistance Point 0.1255
Last Price 0.1102
1st Support Level 0.0995
2nd Support Level 0.0887
3rd Support Level 0.0735

See More

52-Week High 6.8000
Fibonacci 61.8% 4.2238
Fibonacci 50% 3.4280
Fibonacci 38.2% 2.6322
Last Price 0.1102
52-Week Low 0.0560

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies